Ibandronate , 99% , 114084-78-5
| Pack Size | Price | Stock | Quantity |
| 1g | RMB114.40 | In Stock |
|
| 5g | RMB321.60 | In Stock |
|
| 10g | RMB630.40 | In Stock |
|
| 15g | RMB916.80 | In Stock |
|
| 25g | RMB1091.20 | In Stock |
|
| 50g | RMB2073.60 | In Stock |
|
| 100g | RMB3152.00 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 113-115°C |
| Boiling point: | 587.8±60.0 °C(Predicted) |
| Density | 1.449±0.06 g/cm3(Predicted) |
| storage temp. | Sealed in dry,Store in freezer, under -20°C |
| solubility | Aqueous Base (Slightly), Methanol (Slightly), Water (Slightly) |
| form | Solid |
| pka | 1.60±0.10(Predicted) |
| color | White to Off-White |
| Stability: | Hygroscopic |
| CAS DataBase Reference | 114084-78-5(CAS DataBase Reference) |
| EPA Substance Registry System | Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis- (114084-78-5) |
Description and Uses
This third generation biphosphonate was launched in Austria and Germany for the treatment of bone disorders such as hypercalcemia in malignancy and ostedysis, Paget's disease and osteoporosis. It does not effect bone mineralization, therefore, the potential risk of osteomalacia is prevented. This was a problem with first generation derivatives. While the exact mode of action is not understood, they are inhibitors of osteroclast mediated bone resorption. These compounds strongly interact with hydroxyapatite crystals and have a half-life in the skeleton of several years. Despite this observation ibandronate was well tolerated and safe.
A labeled biphosphonate bone resorption inhibitor.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
